HNHA

Item no.	HY-118672-2mg
Manufacturer	MedChem Express
CASRN	926908-04-5
Amount	2 mg
Quantity options	100 mg 10 mg 1 ea 25 mg 2 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.76
Citations	[1]Park KC, et al. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011 Feb;102(2):343-50.
Smiles	O=C(NO)CCCCCCSC1=CC=C2C=CC=CC2=C1
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	HDAC; HIF/HIF Prolyl-Hydroxylase; MMP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	303.42
Product Description	HNHA is a potent histone deacetylase (HDAC) inhibitor. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Isoform	MMP-2; MMP-9
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-118672-2mg-safety-datasheet.pdf